TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00650260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynatherm Medical vitalHEAT Temperature Management System vH2
Description: The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)
Description: The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
Study: NCT00837811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 60 milligrams \[(mg) with potential for dose escalation to 120 mg\] subcutaneously every 4 weeks for 48 weeks
Study: NCT02789202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Treatment of initial dental caries lesion in occlusal surface using the silver diamine fluoride.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnish
Description: Treatment of initial dental caries lesion in occlusal surface using the fluoride varnish
Study: NCT02401438

Intervention type: OTHER
Intervention: 5D ultrasound

Intervention type: OTHER
Intervention: 2D ultrasound
Study: NCT01154764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: I period: CG 100649 II period: Ketoconalzole + CG100649 at the same time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: I period: CG 100649 II period: Ketoconalzole + CG100649 at the same time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: I period: ketoconazole + CG100649 II period: CG 100649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: I period: ketoconazole + CG100649 II period: CG 100649
Study: NCT03996252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% Foam
Description: Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efudex 5% Topical Cream
Description: Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
Study: NCT00491075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 IV Over 10 Minutes on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1500 mg/m\^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.
Study: NCT00064337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study: NCT05514925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection [Avastin]
Description: Intravitreal injection of bevacizumab (1.25 mg, 0.05 ml) in the inferior temporal quadrant of the eye, 4 mm behind the limbus in phakic eyes, and 3.5 mm in pseudophakic eyes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Retinal Cryoapplication
Description: In the operating room under peribulbar anesthesia, four focal conjunctival incisions are made on each quadrant between the muscles insertions. The Tenon capsule is opened with scissors to expose the sclera. Four to six cryo-applications are made per quadrant, at the edge of muscle insertion and a line behind. The exposure time is 4 to 5 seconds. 7-0 resorbable sutures are then put on each quadrant to close the conjunctiva.
Study: NCT01159457

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccination (Sci-B-Vac)
Description: A dose of 5mcg (0.5 ml) (up to 10yr old) and 10mcg (1.0 ml)(above 10yr old) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccination (EngerixB)
Description: A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
Study: NCT01226472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
Study: NCT01407406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB023 - low dose IV Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB023 - low dose IV Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB023 - low dose IV Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB023 - high dose IV Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB023 - high dose IV Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB023 - high dose IV Dose
Study: NCT02035241

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spices 1
Description: In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spices 2
Description: In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spices 3
Description: In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 3. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbs 1
Description: In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbs 2
Description: In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Description: As a control, subjects are asked to consume 200 ml control drinks. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
Study: NCT03199131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right ventricular biopsies
Description: a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Right ventricular biopsies
Description: a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
Study: NCT02683460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patella resurfacing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patella retention
Study: NCT03687476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTS-270
Description: VTS-270 200 mg/mL administered as described in the arm group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTS-270
Description: VTS-270 200 mg/mL administered as described in the arm group description.
Study: NCT04552626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting (social breaks)
Description: Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a short social break. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with step-up exercise break
Description: Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform a simple moderate-intensity step-up exercise for three minutes at a predetermined pace. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with simple resistance activity breaks
Description: Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
Study: NCT00064337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study: NCT01650441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg
Description: In this trial, patients will take two inhalations of the beclometasone dipropionate 100 µg and formoterol fumarate 6 µg combination therapy (Foster®) using a Dry Powder Inhaler (NEXThaler®) device in the morning and two inhalations in the evening, for a total of 4 inhalations a day (total daily dose: BDP 400 µg / FF 24 µg).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT thorax
Description: CT scan of the thorax will be performed at 2 time points: baseline and after 6 months of treatment.~The CT scan will be performed with low dose radiation using the multi-slice CT scan. Scanning will be performed at Functional Residual Capacity and Total Lung Capacity (2 times 8 sec). The lung volumes will be controlled using adapted spirometry during the CT procedure. The radiation dose will be reduced by reduction of the tube current and voltage. These settings depend on the patients' weight (1mAs/kg). In addition to this there will be an increase in noise factor to further reduce the radiation dose.
Study: NCT02201472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI with MRE
Description: Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
Study: NCT04528394

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon
Description: Photon combined with Carbon ion in Arm 1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton
Description: Proton combined with Carbon ion in Arm 2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion
Description: Same dose and fractionation will be used in both arms.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion
Description: Same dose and fractionation will be used in both arms.
Study: NCT00657930

Intervention type: DRUG
Intervention: insulin detemir
Description: observational study - dose and frequency to be prescribed by the physician as a result of standard clinical practice.
Study: NCT01914939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills focused CBT
Study: NCT00064337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT00790023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mcg Ciclesonide
Description: 80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 mcg Ciclesonide
Description: 160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo HFA Inhaler once daily (one actuation per nostril)
Study: NCT01914939

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management/relaxation training

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo drug
Study: NCT05533073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1: Etoricoxib / Tramadol Fixed dose combination
Description: Sachet with granules (Laboratorios Silanes S.A. de C.V.). Formula : 90 mg/ 50 mg Pharmaceutical Form: Sachet with granules Dosage: 100 mL (90 mg/ 50mg) Administration way: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A2: Etoricoxib
Description: Arcoxia®, Schering Plough S.A. de C.V. A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A3: Tramadol
Description: Tradol®, from Grünenthal GMBH. Pharmaceutical Form: Capsule Formula: Each capsule contains 50 mg Dosage: 1 capsule of 50 mg Administration way: oral
Study: NCT00135525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01028040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3043
Description: Intravenous, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3043
Description: Infusion, single dose
Study: NCT00654368

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Commercially available etanercept administered subcutaneously at 50 mg/week.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Commercially available etanercept administered subcutaneously at 50 mg/week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
Study: NCT03275064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LNA043
Description: LNA043 intra-articular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intra-articular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intra-articular injection
Study: NCT01384188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5334
Description: 150 mg for 5 days administered in the morning or in the evening
Study: NCT01603355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Intravenous tocilizumab:~Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks
Study: NCT02927522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
Study: NCT01882491

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Description: Solution for subcutaneous injection
Study: NCT00660023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
Study: NCT01948947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
Study: NCT03308266

Intervention type: DIAGNOSTIC_TEST
Intervention: electromyography
Study: NCT01948947

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
Study: NCT01384188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5334
Description: 150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
Study: NCT03321890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast
Study: NCT02926365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT
Study: NCT00461045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRZ 0.5 mg/m^2
Description: NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
Study: NCT00027898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03321890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: oral, 20mg / day,after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: oral, 50mg / day,after lunch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: oral, 50mg / day,after dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral, 10mg / times, once a week,after breakfast
Study: NCT03531606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mechnicov probiotics
Description: Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'
Study: NCT00027898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03680105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJX
Description: RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).
Study: NCT03531606

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'
Study: NCT00707486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemcon Dental Dressing
Description: The Hemcon Dental Dressing is an oral wound dressing made of chitosan.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze with Pressure and/or Gelfoam
Description: Common practice for oral surgery patients involves the use of sterile dressing over the extraction site. The subject will provide the pressure by biting down on the sterile gauze. As previously discussed, other practices involve the use of Gelfoam prior to application of sterile gauze.
Study: NCT05889169

Intervention type: OTHER
Intervention: Neurorehabilitation
Description: Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)

Intervention type: OTHER
Intervention: Neurorehabilitation
Description: Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)